Prophylactic surgery can reduce the high risk of breast and ovarian cancer among BRCA mutation carriers and can actually improve survival, researchers affirmed. ...

WASHINGTON -- The Food and Drug Administration turned down a request for accelerated approval of Roche-Genentech's trastuzumab-DM1 for treatment of HER2-positive breast cancer. ...

Women who averaged one alcoholic drink a day had almost double the risk of hormone-sensitive breast cancer of nondrinkers, data from the Women's Health Initiative (WHI) showed. ...

Both the duration and composition of hormone therapy (HT) significantly influenced breast cancer risk in postmenopausal women, long-term follow-up in almost 3,000 women showed. ...

The number of white girls developing signs of puberty at a younger age has almost doubled since the late 1990s, researchers found. ...

Having a male relative with breast cancer boosts the family's perception of their own risk but doesn't help the odds that they will do something about it, analysis of national survey data showed. ...

A risk score based on a number of uncommon genetic variants appears to predict risk of estrogen receptor-positive breast cancer but with questionable clinical utility, researchers said. ...

Women in their 40s with breast cancer have tumors that are more difficult to detect with mammography, not faster growing tumors that manifest between screenings, a computer simulation of breast cancer suggests. ...

GAITHERSBURG, Md. -- An advisory panel has voted 12 to 1 to recommend that the FDA remove the advanced breast cancer indication from bevacizumab (Avastin), after two large clinical trials failed to demonstrate a clinically meaningful benefit of the drug, which carries serious side effects. ...

WASHINGTON -- Adding bevacizumab (Avastin) to chemotherapy drugs doesn't increase survival for women with advanced breast cancer, according to FDA documents posted in advance of an advisory panel meeting on Tuesday. ...